Patients With COVID19
Conditions
Brief summary
The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities
Interventions
DRUGHydroxychloroquine
400mg per day during 10 days
DRUGAzithromycin
500 mg per day during 5 days
Sponsors
Eshmoun Clinical Research Center
Dacima Consulting
Abderrahmane Mami Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
open, interventional, multicentric study
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* confirmed COVID19 (+) * Qt\<500ms * no severity criteria * pauci-symptomatique patients * signed consent form
Exclusion criteria
* no confirmed patient COVID19 * severity criteria * known allegies to macrolides and HCQ * Treated with HCQ within 1 month prior to inclusion * hepatitis insufficiency * Renal insufficiency * treatment no indicated with azithro and HCQ * hypovolemia * complete brach block * retinopathia * psoriasis * pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| improvment or healing of clinical signs | at the end of the study treatment - 1 month after inclusion | no respiratory infectious signs |
| Evolution of clinical signs | at the end of the study treatment - 1 month after inclusion | Low respiratory signs with severity criteria |
Countries
Tunisia
Outcome results
None listed